A Phase II Trial of Intraperitoneal High-Dose Carboplatin and Etoposide with Granulocyte Macrophage-Colony Stimulating Factor Support in Patients with Ovarian Carcinoma

McClay, Edward F.; Braly, Patricia; Kirmani, Saeeda; Plaxe, Steven C.; Kim, Sinil; McClay, Mary Eileen; Wilgus, Linda; Howell, Stephen B.

doi:10.1097/00000421-199502000-00005

Cited by 15 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been a few reports demonstrating response rates of 69–74% with IP carboplatin in the second‐line setting (8,9) .…”

Section: Ip Carboplatin Why Not?mentioning

confidence: 99%

“…There have been a few reports demonstrating response rates of 69-74% with IP carboplatin in the second-line setting (8,9) . In 2003, Fujiwara et al (10) published the survival data of 165 patients with epithelial ovarian cancer who underwent IP carboplatin-based chemotherapy as a first-line treatment.…”

Section: Clinical Efficacy Of Ip Carboplatin-based Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Can carboplatin replace cisplatin for intraperitoneal use?

Fujiwara

2008

Int J Gynecol Cancer

View full text Add to dashboard Cite

Intraperitoneal (IP) chemotherapy is theoretically a feasible route for treating ovarian cancer. It is possible to expose tumor tissue disseminated peritoneal surface to extremely high concentration of anticancer agents. Three large-scale, randomized trials conducted in the US have demonstrated a significant improvement of progression survival and/or overall survival in IP chemotherapy arm over intravenous arm. Despite these favorable results, IP chemotherapy has not been accepted as standard care. One of the reasons for this is the use of cisplatin, which has been replaced by the less toxic platinum agent, carboplatin, when administered intravenously. In this review article, we discuss why IP chemotherapy using carboplatin has been ignored and its future potential.

show abstract

“…There have been a few reports demonstrating response rates of 69–74% with IP carboplatin in the second‐line setting (8,9) .…”

Section: Ip Carboplatin Why Not?mentioning

confidence: 99%

Section: Clinical Efficacy Of Ip Carboplatin-based Chemotherapymentioning

confidence: 99%

Can carboplatin replace cisplatin for intraperitoneal use?

Fujiwara

2008

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…The dose of cisplatin was 100 mg/m 2 for both groups, and the treatment was repeated every 3 weeks for six cycles. In the 546 eligible patients, the estimated median survival was significantly longer in the IP group (49 months; 95% CI 42-56) compared to the IV group (41 months; 95% CI [34][35][36][37][38][39][40][41][42][43][44][45][46][47]. The hazard ratio for the risk of death was 0.76 (95% CI 0.61-0.96; P ¼ 0.02) in favor of IP therapy (Fig.…”

Section: Phase II Trialsmentioning

confidence: 95%

“…A number of phase II trials have been reported regarding IP chemotherapy for ovarian cancer as summarized in Table 3 (32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50) . However, it is difficult to compare the efficacy of those agents in these phase II studies because the choice of patient population is different.…”

Section: Phase II Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Principles and practice of intraperitoneal chemotherapy for ovarian cancer

Fujiwara

Armstrong

Morgan

et al. 2007

Int J Gynecol Cancer

View full text Add to dashboard Cite

Intraperitoneal (IP) chemotherapy has been studied for years to improve the survival of patients with ovarian cancer. Recently, the result of Gynecologic Oncology Group 172 trial comparing IP versus intravenous administration of cisplatin-based chemotherapy was published, demonstrating the improvement of survival benefit in favor of the IP arm. This trial is the third trial that showed a survival benefit on IP chemotherapy. The National Cancer Institute (NCI) and Gynecologic Oncology Group have done a meta-analysis on the results of these three US trials and other phase III trials of IP versus intravenous chemotherapy, and significant improvement of survival was shown with IP therapy. Based on this meta-analysis, NCI has released a clinical announcement encouraging the gynecological oncology community to consider IP chemotherapy as the standard treatment for optimally debulked advanced ovarian cancer patients. However, there still are controversial issues regarding the use of IP chemotherapy. It is important to understand how IP chemotherapy works to solve those issues in the future. In this review article, we discuss the principles and clinical aspects of IP chemotherapy and also discuss the current problems and future perspectives in IP chemotherapy.

show abstract